Press release
Rheumatoid Arthritis Pipeline, Clinical Trials, Emerging Drugs, FDA Approvals 2024 (Updated)
Rheumatoid Arthritis Pipeline
Key Takeaways from the Rheumatoid Arthritis Pipeline Report
• DelveInsight's Rheumatoid Arthritis pipeline report depicts a robust space with 95+ active players working to develop 100+ pipeline therapies for Rheumatoid Arthritis treatment.
• The leading companies working in the Rheumatoid Arthritis Market include Yuyu Pharma Inc., Worg Pharmaceuticals, Vyne Therapeutics, Vaccinex Inc., Tiziana Life Sciences, Teijin Pharma, Taiho Pharmaceutical, Synermore Biologics Co., Ltd., Synact Pharma, Sorrento Therapeutics, Sonoma Biotherapeutics, SinoMab Bioscience Ltd, Silo Pharma, SFA Therapeutics, Servatus Biopharmaceuticals, SciRhom, R-Pharm, Rottapharm Biotech, ROS Therapeutics, RheumaGen, Revolo Biotherapeutics, RemeGen, Regen BioPharma Inc. PrecisionLife, Philogen, Pfizer, Oryn Therapeutics, Nurix, NovImmune, Novartis, Neutrolis Therapeutics, MyMD Pharmaceuticals, Modern Biosciences, Minghui Pharmaceutical Pty Ltd, MetrioPharm, Mesoblast, Lysatpharma GmbH, Lynk Pharmaceuticals, Landos Biopharma, Kymera Therapeutics, Kolon TissueGene, KLUS Pharma, Kiniksa Pharmaceuticals, Ltd., Kangstem Biotech, Jubilant Therapeutics, Jiangsu Hengrui Medicine, Janssen Research & Development, Intrinsic Medicine, Innocare Pharma Australia Pty Ltd, Immutep Limited, Imcyse, I-Mab Biopharma Co. Ltd., Iltoo Pharma, IGM Biosciences Inc., ICMBIO, and others.
• Promising Rheumatoid Arthritis Pipeline Therapies in the various stages of development etanercept, M2951, Adalimumab, methotrexate, ENBREL®, Enbrel, Certolizumab pegol, LY3871801, and others.
• March 2024: Eli Lilly and Company announced a study of Phase 4 clinical trials for Baricitinib. This post-marketing study is designed to compare the safety of baricitinib versus tumor necrosis factor (TNF) inhibitors with respect to venous thromboembolic events (VTEs) when given to participants with rheumatoid arthritis.
• January 2024: Attune Health Research, Inc- Patients will be assigned to receive either Depo Medrol or Acthar treatment. A synovial biopsy, blood draws, synovial fluid aspiration, and physician assessments will be performed before and after initiating treatment.
Request a sample and discover the recent advances in Rheumatoid Arthritis Treatment Drugs @ Rheumatoid Arthritis Pipeline Outlook Report- https://www.delveinsight.com/report-store/rheumatoid-arthritis-ra-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
In the Rheumatoid Arthritis pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Rheumatoid Arthritis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Rheumatoid Arthritis Overview
Rheumatoid arthritis (RA) is an autoimmune or chronic inflammatory disease known to adversely impact the joints of the body. An autoimmune disorder is a condition where the immune system starts making antinuclear bodies instead of antibodies which directs them to cause self-injury to the body; on the onset of disease, the immune response primarily attacks and harms the joints.
Find out more about Rheumatoid Arthritis Treatment Landscape @ Drugs for Rheumatoid Arthritis Treatment- https://www.delveinsight.com/sample-request/rheumatoid-arthritis-ra-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Rheumatoid Arthritis Emerging Drugs Profile
• SM03: SinoMab
• SHR0302: Jiangsu Hengrui Medicine
• RC18: RemeGen
• Zalunfiban: CeleCor Therapeutics
• ABBV-3373: Abbvie
• Dazodalibep: Horizon Therapeutics
• AP1189: Synact Pharma
• Dekavil: Philogen
Rheumatoid Arthritis Pipeline Therapeutics Assessment
There are approx. 95+ key companies which are developing the Rheumatoid Arthritis therapies. The Rheumatoid Arthritis companies which have their Rheumatoid Arthritis drug candidates in the most advanced stage, i.e. Phase I/II include, RHEACELL.
DelveInsight's Rheumatoid Arthritis pipeline report covers around 100+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
Rheumatoid Arthritis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal
Rheumatoid Arthritis Products have been categorized under various Molecule types such as
• Oligonucleotide
• Peptide
• Small molecule
Learn more about the emerging Rheumatoid Arthritis Pipeline Therapies @ Rheumatoid Arthritis Clinical Trials Assessment- https://www.delveinsight.com/sample-request/rheumatoid-arthritis-ra-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Rheumatoid Arthritis Pipeline Report
• Coverage- Global
• Rheumatoid Arthritis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Rheumatoid Arthritis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Rheumatoid Arthritis Companies- Yuyu Pharma Inc., Worg Pharmaceuticals, Vyne Therapeutics, Vaccinex Inc., Tiziana Life Sciences, Teijin Pharma, Taiho Pharmaceutical, Synermore Biologics Co., Ltd., Synact Pharma, Sorrento Therapeutics, Sonoma Biotherapeutics, SinoMab Bioscience Ltd, Silo Pharma, SFA Therapeutics, Servatus Biopharmaceuticals, SciRhom, R-Pharm, Rottapharm Biotech, ROS Therapeutics, RheumaGen, Revolo Biotherapeutics, RemeGen, Regen BioPharma Inc. PrecisionLife, Philogen, Pfizer, Oryn Therapeutics, Nurix, NovImmune, Novartis, Neutrolis Therapeutics, MyMD Pharmaceuticals, Modern Biosciences, Minghui Pharmaceutical Pty Ltd, MetrioPharm, Mesoblast, Lysatpharma GmbH, Lynk Pharmaceuticals, Landos Biopharma, Kymera Therapeutics, Kolon TissueGene, KLUS Pharma, Kiniksa Pharmaceuticals, Ltd., Kangstem Biotech, Jubilant Therapeutics, Jiangsu Hengrui Medicine, Janssen Research & Development, Intrinsic Medicine, Innocare Pharma Australia Pty Ltd, Immutep Limited, Imcyse, I-Mab Biopharma Co. Ltd., Iltoo Pharma, IGM Biosciences Inc., ICMBIO, and others.
• Rheumatoid Arthritis Pipeline Therapies- etanercept, M2951, Adalimumab, methotrexate, ENBREL®, Enbrel, Certolizumab pegol, LY3871801, and others.
Dive deep into rich insights for new drugs for Rheumatoid Arthritis treatment, Visit @ Rheumatoid Arthritis Market Drivers and Barriers, and Future Perspective- https://www.delveinsight.com/sample-request/rheumatoid-arthritis-ra-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Introduction
2. Executive Summary
3. Rheumatoid Arthritis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Rheumatoid Arthritis - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. SM03: SinoMab
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. ABBV-3373: Abbvie
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. SVT 6A4710: Servatus Biopharmaceuticals
15. Drug profiles in the detailed report…..
16. Early Stage Products (Phase I)
17. SYN060: Synermore Biologics Co., Ltd.
18. Drug profiles in the detailed report…..
19. Preclinical Stage Products
20. CABA-201: Cabaletta Bio
21. Drug profiles in the detailed report…..
22. Inactive Products
23. Rheumatoid Arthritis Collaborations Assessment- Licensing / Partnering / Funding
24. Rheumatoid Arthritis Unmet Needs
25. Rheumatoid Arthritis Market Drivers and Barriers
26. Appendix
For further information on the Rheumatoid Arthritis pipeline therapeutics, reach out to Rheumatoid Arthritis Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/rheumatoid-arthritis-ra-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
List of Other Important Links-
Stem Cell Market- https://www.delveinsight.com/report-store/stem-cell-market
Vulvar Cancer Market- https://www.delveinsight.com/report-store/vulvar-cancer-market
Vascular Grafts Market- https://www.delveinsight.com/report-store/vascular-grafts-market
Acne Vulgaris Market- https://www.delveinsight.com/report-store/acne-vulgaris-av-market
Bone Growth Stimulator Market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market
Lactose Intolerance Market- https://www.delveinsight.com/report-store/lactose-intolerance-market
Angiofibroma Market- https://www.delveinsight.com/report-store/angiofibroma-market
Atopic Dermatitis Market- https://www.delveinsight.com/report-store/atopic-dermatitis-market
Sepsis Market- https://www.delveinsight.com/report-store/sepsis-market
Tendonitis Market- https://www.delveinsight.com/report-store/tendonitis-market
Fabry Disease Market- https://www.delveinsight.com/report-store/fabry-disease-market
Ascites Market- https://www.delveinsight.com/report-store/ascites-market
Systemic Lupus Erythematosus Market- https://www.delveinsight.com/report-store/systemic-lupus-erythematosus-market
Post Operative Pain Management Market- https://www.delveinsight.com/report-store/post-operative-pain-management-market
Cxcr Inhibitors Market- https://www.delveinsight.com/report-store/c-x-c-chemokine-receptor-inhibitors-competitive-landscape-market-and-pipeline-analysis
Androgen Receptor Inhibitor Market- https://www.delveinsight.com/report-store/androgen-receptor-inhibitor-market-forecast
Antibody Drug Conjugate Market- https://www.delveinsight.com/report-store/antibody-drug-conjugate-adc-market
STS Devices Market- https://www.delveinsight.com/report-store/sts-devices-market
Positive Airway Pressure Device Market- https://www.delveinsight.com/report-store/positive-airway-pressure-device-market
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Rheumatoid Arthritis Pipeline, Clinical Trials, Emerging Drugs, FDA Approvals 2024 (Updated) here
News-ID: 3527877 • Views: …
More Releases from DelveInsight Business Research LLP
Sjogren's Syndrome Pipeline Appears Robust With 15+ Key Pharma Companies Activel …
DelveInsight's, "Sjogren's syndrome Pipeline Insight, 2025" report provides comprehensive insights about 15+ companies and 20+ pipeline drugs in Sjogren's syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Sjogren's Syndrome Research. Learn more about…
MELAS Syndrome Pipeline Appears Robust With 4+ Key Pharma Companies Actively Wor …
DelveInsight's "MELAS Syndrome Pipeline Insight, 2025" report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in MELAS Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in MELAS Syndrome Research. Learn more about…
Autism Spectrum Disorder Pipeline Appears Robust With 18+ Key Pharma Companies A …
DelveInsight's, "Autism Spectrum Disorder Pipeline Insight, 2025" report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in Autism Spectrum Disorder pipeline landscape. It covers the Autism Spectrum Disorder pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, clinical stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in…
Familial Adenomatous Polyposis Pipeline Appears Robust With 4+ Key Pharma Compan …
"DelveInsight's, "Familial adenomatous polyposis Pipeline Insight, 2025" report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Familial adenomatous polyposis pipeline landscape. It covers the Familial Adenomatous Polyposis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Familial Adenomatous Polyposis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our…
More Releases for Rheumatoid
Rheumatoid Arthritis Pipeline Outlook Report 2024
DelveInsight's, "Rheumatoid Arthritis Pipeline Insight 2024" report provides comprehensive insights about 95+ companies and 100+ pipeline drugs in the Rheumatoid Arthritis pipeline landscape. It covers the Rheumatoid Arthritis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Rheumatoid Arthritis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the…
Rheumatoid Arthritis Therapeutics Market - Relieving Pain, Restoring Mobility: R …
Newark, New Castle, USA: The "Rheumatoid Arthritis Therapeutics Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Rheumatoid Arthritis Therapeutics Market: https://www.growthplusreports.com/report/rheumatoid-arthritis-therapeutics-market/7891
This latest report researches the industry structure,…
Smart Pills to Rejuvenate the Rheumatoid Arthritis Market
The Rheumatoid Arthritis Market is expected to climb up the ladder of persistence in the next decade. With various healthcare apps on the anvil, there are also mindfulness apps being tabled. They fall in the category of "Wellness apps". With the world wishing for the post-Covid era to function smoothly, these wellness apps are expected to take the healthcare vertical by storm further.
Worldwide sales of rheumatoid arthritis diagnosis test kits…
Vertical Saas to Supplement the Rheumatoid Arthritis Treatment Market
The global Rheumatoid Arthritis Treatment Market is estimated to grow noticeably in the next 10 years. With personalization doing the rounds, the healthcare vertical is also not expected to escape. With digitization, not just the track record of the patient but also the precautionary measures to be taken could be put forth. This would be how the healthcare vertical go about in the subsequent period.
Rising occurrence of rheumatoid arthritis because…
The Rheumatoid Arthritis Treatment Market To Witness Calculated Innovation
The global Rheumatoid Arthritis Treatment Market is there to grow at a noteworthy In Upcoming Years. These days, pre-empt process breakdowns by making use of AI are the ongoing trend. Regulatory compliance is also being adhered to using data masking. Personalized smart videos are being used to render proper member communication. These, and many such digitally transformative approaches are being followed in the enterprise as of now and the scenario…
Rheumatoid Arthritis Therapeutics Market - Forecasts to 2026
As per the research conducted by GME, the Rheumatoid Arthritis Therapeutics Market is estimated to be valued at USD 25.66 billion in 2021 and is projected to reach USD 32.44 billion by 2026 at a CAGR of 4.8%. The increasing chronic diseases, growing joint deformities requiring treatment, growing inflammatory diseases, increasing emergence of biologics, growing autoimmune disorders, mounting demand and desire for novel therapeutics that are riding medical facilities, growing…
